Table 2.
Reports of previous studies regarding of comparison of clinical outcomes in younger and elderly patients treated with locoregional therapies for hepatocelluar carcinoma.
| Author /year/country |
Treatment | Child- Pugh |
Definition of elderly patient | No. of patient | OS | R(D)FS | Morbidity rate | Mortality rate | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Y | E | Y | E | Y | E | Y | E | Y | E | ||||
| Tateishi et al /2005/Japan 77 |
RFA | A/B | ≥68 years | 160 | 159 | 79.2% (3-year) |
76%** (3-year) |
NA | NA | NA | NA | NA | NA |
| Takahashi et al /2010/Japan 22 |
RFA | A/B | ≥75 years | 354 | 107 | 80% (3-year) |
82%** (3-year) |
49% (3-year) |
49%** (3-year) |
3.7% | 2.8%** | 0% | 0%** |
| Mirici-Cappa et al /2010/Italy 32 |
RFA or PEI | A/B/C | ≥70 years | 230 | 195 | 52.9% (3-year) |
53.4%** (3-year) |
NA | NA | NA | NA | NA | NA |
| Kao et al /2012/Taiwan 23 |
RFA | A/B | ≥65 years | 100 | 158 | 87% (3-year) |
83.1%* (3-year) |
39.8% (3-year) |
21.9%* (3-year) |
NA | NA | NA | NA |
| Nishikawa et al /2012/Japan 21 |
RFA | A/B | ≥75 years | 238 | 130 | 83.7% (3-year) |
64.1%* (3-year) |
40.0% (3-year) |
21.3%* (3-year) |
1.3% | 2.3%** | 0% | 0%** |
| Poon et al /1999/China 27 |
TACE | A/B | ≥70 years | 317 | 67 | 18% (3-year) |
25%** (3-year) |
NA | NA | 26% | 24%** | 5% | 7%** |
| Yau et al /2009/China 44 |
TACE | A/B/C | ≥70 years | 843 | 197 | 14.9% (3-year) |
23.2%* (3-year) |
NA | NA | 27% | 24%** | 3.5% | 4.7%** |
| Mirici-Cappa et al /2010/Italy 32 |
TACE | A/B/C | ≥70 years | 396 | 158 | 32.0% (3-year) |
36.4%** (3-year) |
NA | NA | NA | NA | NA | NA |
| Cohen et al /2013/Israel 14 |
TACE | A/B/C | ≥75 years | 38(<65yr)/ 41(65-75yr) |
23 | 31%/ 48% (3-year) |
23%** (3-year) |
NA | NA | NA | NA | NA | NA |
OS; overall survival, R(D)FS; recurrence (disease)-free survival, Y; younger patients, E; elderly patients, RFA; radiofrequency ablation, PEI; percutaneous ethanol injection, TACE; transcatheter arterial chemoembolization, NA; not available, * statistically significant, ** statistically not significant.